Xi Zhang1, Nadia Harbeck1, Udo Jeschke1, Sophie Doisneau-Sixou2,3. 1. Brustzentrum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Klinikum der Ludwig-Maximilians-Universität, Maistraße 11, 80337, Munich, Germany. 2. Brustzentrum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Klinikum der Ludwig-Maximilians-Universität, Maistraße 11, 80337, Munich, Germany. sophie.doisneausixou@med.lmu.de. 3. Faculté des Sciences Pharmaceutiques, Université Paul Sabatier Toulouse III, 31062, Toulouse Cedex 09, France. sophie.doisneausixou@med.lmu.de.
Abstract
PURPOSE: Breast cancer is a significant global public health issue. It is the leading cause of death among women around the world, with an incidence increasing annually. In recent years, there has been more and more information in the literature regarding a protective role of vitamin D in cancer. Increasingly preclinical and clinical studies suggest that vitamin D optimal levels can reduce the risk of breast cancer development and regulate cancer-related pathways. METHOD: In this review, we focus on the importance of vitamin D in breast cancers, discussing especially the influence of vitamin D signaling on estrogen receptor and human epidermal growth factor receptor 2 (HER2), two major biomarkers of breast cancer today. CONCLUSION: We discuss the possibility of actual and future targeted therapeutic approaches for vitamin D signaling in breast cancer.
PURPOSE:Breast cancer is a significant global public health issue. It is the leading cause of death among women around the world, with an incidence increasing annually. In recent years, there has been more and more information in the literature regarding a protective role of vitamin D in cancer. Increasingly preclinical and clinical studies suggest that vitamin D optimal levels can reduce the risk of breast cancer development and regulate cancer-related pathways. METHOD: In this review, we focus on the importance of vitamin D in breast cancers, discussing especially the influence of vitamin D signaling on estrogen receptor and human epidermal growth factor receptor 2 (HER2), two major biomarkers of breast cancer today. CONCLUSION: We discuss the possibility of actual and future targeted therapeutic approaches for vitamin D signaling in breast cancer.
Entities:
Keywords:
Breast cancer; Estrogen receptor; HER2; Vitamin D; Vitamin D receptor
Authors: Erin M Olson; Julie S Najita; Jessica Sohl; Amal Arnaout; Harold J Burstein; Eric P Winer; Nancy U Lin Journal: Breast Date: 2013-01-23 Impact factor: 4.380
Authors: Matthew W Carson; Jun Zhang; Michael J Chalmers; Wayne P Bocchinfuso; Karol D Holifield; Thierry Masquelin; Ryan E Stites; Keith R Stayrook; Patrick R Griffin; Jeffery A Dodge Journal: Bioorg Med Chem Lett Date: 2014-05-29 Impact factor: 2.823
Authors: R R Buras; L M Schumaker; F Davoodi; R V Brenner; M Shabahang; R J Nauta; S R Evans Journal: Breast Cancer Res Treat Date: 1994 Impact factor: 4.872
Authors: Itay Pickholtz; Shira Saadyan; Gilmor I Keshet; Victor S Wang; Rachel Cohen; Peter Bouwman; Jos Jonkers; Stephen W Byers; Moshe Z Papa; Ronit I Yarden Journal: Oncotarget Date: 2014-12-15
Authors: Katarzyna Dzik; Wojciech Skrobot; Damian Jozef Flis; Mateusz Karnia; Witold Libionka; Wojciech Kloc; Jan Jacek Kaczor Journal: Eur J Appl Physiol Date: 2017-11-15 Impact factor: 3.078
Authors: Ji Su Kim; Caspar Christian Haule; Joo Heung Kim; Sung Mook Lim; Kwang Hyun Yoon; Jee Ye Kim; Hyung Seok Park; Seho Park; Seung Il Kim; Young Up Cho; Byeong-Woo Park Journal: J Breast Cancer Date: 2018-06-20 Impact factor: 3.588